Actavis acquires remaining stake in Turkish pharmaceutical company Fako
Actavis acquired an 89% stake in Fako in December 2003 for an initial purchase price of US$63 million. In addition, Actavis agreed to provide Fako with up to US$15 million to assist its funding requirements.
Fako is Turkey's fifth-largest generic pharmaceutical company, specialising in the development, production and sales of pharmaceuticals. It has a total workforce of around 1,200 employees. Along with its headquarters in Istanbul, the company has 10 sales offices throughout Turkey. Fako also develops and produces active pharmaceutical ingredients.
Most read news
Other news from the department business & finance
These products might interest you
AZURA Purifier + LH 2.1 by KNAUER
Preparative Liquid Chromatography - New platform for more throughput
Save time and improve reproducibility during purification
Pharmaceutical Substances by Thieme Verlag
Look up Industrial Syntheses of 2,600 APIs
Your tool for Syntheses, Patents and Applications – Pharmaceutical Substances
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.